RESUMO
CASO CLÍNICO: Se expone el caso de dos hermanos que presentaron neovascularización coroidea asociada a estrías angioides. Ambos pacientes fueron tratados con una inyección mensual de ranibizumab (Lucentis®) intravítrea durante tres meses. La visión se estabilizó y la angiografía fluoresceínica mostró resolución completa de la neovascularización coroidea. Durante el seguimiento, no observamos recurrencia del cuadro. DISCUSIÓN: El uso de ranibizumab intravítreo en caso de neovascularización coroidea asociada a estrías angioides ha mostrado resultados favorables. No obstante, serán necesarias series de casos mayores que nos permitan conocer la verdadera eficacia de este tratamiento
CASE REPORT: We report a familial case of 2 brothers that suffered choroidal neovascularization (CNV) secondary to angioid streaks. They were both treated with a monthly intravitreal injection of ranibizumab (Lucentis®) for 3 months. Visual acuity was stabilized and fluorescein angiography revealed complete resolution of CNV. Neither recurrent CNV lesion nor new hemorrhages were reported during the follow-up period. Discussion: The use of intravitreal ranibizumab for the treatment of CNV in patients with angioid streaks has shown favorable results. However, further studies with a longer follow-up and larger number of patients are necessary to more precisely determine the results of this therapy
Assuntos
Humanos , Masculino , Neovascularização de Coroide/etiologia , Estrias Angioides/complicações , Anticorpos Monoclonais/administração & dosagem , Pseudoxantoma Elástico/diagnósticoRESUMO
CASE REPORT: We report a familial case of 2 brothers that suffered choroidal neovascularization (CNV) secondary to angioid streaks. They were both treated with a monthly intravitreal injection of ranibizumab (Lucentis(®)) for 3 months. Visual acuity was stabilized and fluorescein angiography revealed complete resolution of CNV. Neither recurrent CNV lesion nor new hemorrhages were reported during the follow-up period. DISCUSSION: The use of intravitreal ranibizumab for the treatment of CNV in patients with angioid streaks has shown favorable results. However, further studies with a longer follow-up and larger number of patients are necessary to more precisely determine the results of this therapy.
Assuntos
Estrias Angioides/complicações , Neovascularização de Coroide/etiologia , Estrias Angioides/genética , Neovascularização de Coroide/genética , Feminino , Humanos , Masculino , Pessoa de Meia-IdadeRESUMO
CASE REPORT: We present a case of a patient with subretinal hemorrhage treated with intravitreal r-TPA, SF-6 and ranibizumab. DISCUSSION: Subretinal hemorrhages secondary to age-related macular degeneration are associated with poor visual outcome. A wide variety of management approaches has been developed, but the prognosis of these patients has not been modified by any of them. The association of an intravitreal anti VEGF drug to r-TPA and gas, may improve its results as we add the treatment of the subjacent etiology to the pneumatic displacement.
Assuntos
Inibidores da Angiogênese/uso terapêutico , Anticorpos Monoclonais/uso terapêutico , Hemorragia Retiniana/terapia , Hexafluoreto de Enxofre/uso terapêutico , Ativador de Plasminogênio Tecidual/uso terapêutico , Idoso de 80 Anos ou mais , Inibidores da Angiogênese/administração & dosagem , Anticorpos Monoclonais/administração & dosagem , Anticorpos Monoclonais Humanizados , Neovascularização de Coroide/complicações , Terapia Combinada , Quimioterapia Combinada , Emergências , Humanos , Injeções Intraoculares , Degeneração Macular/complicações , Degeneração Macular/tratamento farmacológico , Masculino , Paracentese , Ranibizumab , Proteínas Recombinantes/administração & dosagem , Proteínas Recombinantes/uso terapêutico , Recidiva , Hemorragia Retiniana/tratamento farmacológico , Hemorragia Retiniana/etiologia , Hemorragia Retiniana/cirurgia , Ativador de Plasminogênio Tecidual/administração & dosagem , Corpo VítreoRESUMO
Caso clínico: Se presenta el caso de un paciente con hemorragia subretiniana por degeneraciónmacular asociada a la edad (DMAE) tratada con activador del plasminógeno tisularrecombinante (r-TPA), hexafluoruro de azufre y ranibizumab.Discusión: Las hemorragias subretinianas secundarias a DMAE tienen mal pronóstico visual.A pesar de la gran cantidad de opciones terapéuticas planteadas para este proceso,ninguna ha conseguido mejorarlo. El desplazamiento de la hemorragia subretiniana conr-TPA y gas se ha aplicado en el tratamiento de esta afección. La asociación de un fármacoanti-VEGF intravítreo a esta técnica puede mejorar los resultados, al asociar un componenteterapéutico al desplazamiento físico de la hemorragia(AU)
Case report: We present a case of a patient with subretinal hemorrhage treated withintravitreal r-TPA, SF-6 and ranibizumab.Discussion: Subretinal hemorrhages secondary to age-related macular degeneration areassociated with poor visual outcome. A wide variety of management approaches has beendeveloped, but the prognosis of these patients has not been modified by any of them. Theassociation of an intravitreal anti VEGF drug to r-TPA and gas, may improve its results aswe add the treatment of the subjacent etiology to the pneumatic displacement(AU)
